Héctor Montoya-Fuentes

Dr. Héctor Montoya-Fuentes

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2000 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
MPManuel Peñaloza-Plascencia
Manuel Peñaloza-Plascencia
HMHéctor Montoya-Fuentes
Héctor Montoya-Fuentes
SFSilvia Esperanza Flores-Martínez
Silvia Esperanza Flores-Martínez
FFFrancisco Javier Fierro-Velasco
Francisco Javier Fierro-Velasco
JPJosé Manuel Peñaloza-González
José Manuel Peñaloza-González
JSJosé Sánchez-Corona
José Sánchez-Corona
RECURRENT respiratory papillomatosis (RRP) is the most frequent benign laryngeal neoplasm, affecting children from the earliest months until adolescence.1 Its approximate incidence is 4.3 per 100,0001; 3870 cases are expected in the Mexican infant population, without sex distinction. It is a benign tumor that rarely becomes malignant after radiotherapy. It begins with a mild dysphonia, which may progress to aphonia, but without signs of respiratory insufficiency. Nevertheless, the clinical findings may be complicated by cough with scarce expectoration, which can result in pneumonia with retention of secretion, acute respiratory insufficiency, and asphyxia.2

30 March 2008 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
AMAdriana Patricia Mendizabal
Adriana Patricia Mendizabal
AMAlejandro Morales
Alejandro Morales
Javier Ramirez JiranoJavier Ramirez Jirano
Javier Ramirez Jirano
MPM. Padilla-Rosas
M. Padilla-Rosas
María Cristina Morán MoguelMaría Cristina Morán Moguel
María Cristina Morán Moguel
HMHéctor Montoya-Fuentes
Héctor Montoya-Fuentes

Verified
Journal Article
Open access
PDF file
Daniel Osmar Suárez-RicoDaniel Osmar Suárez-Rico
Daniel Osmar Suárez-Rico
LTLourdes del Carmen Rizo de la Torre
Lourdes del Carmen Rizo de la Torre
MZMartin Zermeño-Ruiz
Martin Zermeño-Ruiz
LALuis Ricardo Balleza Alejandri
Luis Ricardo Balleza Alejandri
Jesus Jonathan García-GalindoJesus Jonathan García-Galindo
Jesus Jonathan García-Galindo
Alberto Beltrán-RamírezAlberto Beltrán-Ramírez
Alberto Beltrán-Ramírez
Persistent high-risk human papillomavirus infection is a critical prerequisite for cervical intraepithelial neoplasia and cervical cancer, yet viral factors alone do not fully explain why most infections clear while a subset persists and progresses. Emerging longitudinal, multi-omics, and mechanistic evidence supports a plausible model in which the cervicovaginal microbiota is not a passive bystander but a functional determinant of mucosal immunity, epithelial barrier integrity, and local metabolic tone. Lactobacillus-dominant community states, particularly those enriched in Lactobacillus crispatus, are generally associated with lower pH, regulated inflammatory signaling, stronger barrier function, and a higher likelihood of HPV clearance. In contrast, anaerobe-enriched dysbiosis is linked to elevated pro-inflammatory cytokines, altered antigen presentation, immune checkpoint signatures consistent with T-cell dysfunction, and metabolic shifts involving lactate depletion and accumulation of short-chain fatty acids and other metabolites that can influence epithelial and immune-cell programs. Importantly, the interaction is bidirectional: hrHPV can remodel the microenvironment by suppressing host defense peptides and perturbing mucosal barriers, thereby reducing Lactobacillus fitness and reinforcing dysbiosis in a feed-forward loop that favors persistence and oncogenic progression. This review integrates functional ecology, longitudinal clinical evidence, immunological and metabolic mechanisms, and translational implications, highlighting opportunities for microbiome-informed risk stratification and adjunctive interventions, as well as key gaps requiring standardized longitudinal multi-omics and rigorously designed clinical trials.

25 March 2018 in International Journal of Immunogenetics
Verified
Journal Article
Closed access
PDF file
JLJ. J. López‐Jiménez
J. J. López‐Jiménez
DPD. I. Peña‐Iñiguez
D. I. Peña‐Iñiguez
AFA. L. Fletes‐Rayas
A. L. Fletes‐Rayas
SFS. E. Flores‐Martínez
S. E. Flores‐Martínez
JSJ. Sánchez‐Corona
J. Sánchez‐Corona
HMHéctor Montoya-Fuentes
Héctor Montoya-Fuentes

26 July 2023 in Cells
Verified
Journal Article
Open access
PDF file
Martha GallegosMartha Gallegos
Martha Gallegos
AGAsbiel Felipe Garibaldi-Ríos
Asbiel Felipe Garibaldi-Ríos
JCJose Israel Cruz
Jose Israel Cruz
LVLuis Eduardo Figuera Villanueva
Luis Eduardo Figuera Villanueva
CRCarlos Alberto Ronquillo-Carreón
Carlos Alberto Ronquillo-Carreón
GZGuillermo Zúñiga-González
Guillermo Zúñiga-González
Colorectal cancer (CRC) is a major global health challenge and one of the top 10 cancers in Mexico. Lifestyle and genetic factors influence CRC development, prognosis, and therapeutic response; identifying risk factors, such as the genes involved, is critical to understanding its behavior, mechanisms, and prognosis. The association between KRAS gene variants (rs8720 and rs12587) and CRC in the Mexican population was analyzed. We performed in silico analysis and analyzed 310 healthy individuals and 385 CRC patients using TaqMan assays and real-time PCR. The CC and GG genotypes of rs8720 and rs12587 were identified as CRC risk factors (p < 0.05). The CC and TC genotypes of the rs8720 were associated with rectal cancer, age over 50 years, moderately differentiated histology, and advanced cancer stage. TG and GG genotypes of the rs12587 variant were a risk factor in the CRC group, in patients with stage I–II, males, and stage III–IV non-chemotherapy response. The TG haplotype is protected against CRC. The combined CCGG genotype was linked to CRC risk. In silico analysis revealed that the rs12587 and rs8720 variants could influence KRAS gene regulation via miRNAs. In conclusion, rs8720 and rs12587 variants of the KRAS gene were associated with CRC risk and could influence KRAS regulation via miRNAs.

1 February 2023 in Viral Immunology
Verified
Journal Article
Closed access
MVMónica Edith Villanueva-Aguilar
Mónica Edith Villanueva-Aguilar
LRLourdes del Carmen Rizo-De-La-Torre
Lourdes del Carmen Rizo-De-La-Torre
MGMaría del Pilar Granados-Muñiz
María del Pilar Granados-Muñiz
AMAndrea Montoya-Fuentes
Andrea Montoya-Fuentes
HMHéctor Montoya-Fuentes
Héctor Montoya-Fuentes
Dengue virus (DENV) is the causal agent of dengue fever. The symptoms and signs of dengue vary from febrile illness to hemorrhagic syndrome. IFITM3 and TNFA are genes of the innate immune system. Variants IFITM3 (rs12252 T>C) and TNFA (rs1800629 G > A and rs361525 G>A) might alter gene expression and change the course of the disease. Our first objective was to determine whether these variants were associated with the susceptibility and severity of dengue. The second was to assess the association of these variants with each symptom. We studied 272 cases with suspected dengue infection, of which 102 were confirmed dengue cases (DENV+) and 170 were dengue-like cases without DENV infection (DENV−). Samples of 201 individuals from the general population of Mexico were included as a reference. Genotyping was performed by the polymerase chain reaction-restriction fragment length polymorphism technique. Odds ratios and confidence intervals were calculated using Pearson's chi-square test and later adjusted for age and sex with a binary logistic regression model. Haldane correction is applied when necessary. We found a significantly higher frequency of the A allele of TNFA rs361525 in both the DENV+ and DENV− groups compared with the general population. Focusing on DENV+ and DENV−, the frequency of the A allele of TNFA rs361525 was higher in the DENV+ group. A broad spectrum of symptoms was related to the A allele of both TNFA variants. We conclude that TNFA rs361525 increases the susceptibility to symptomatic dengue but can also be associated with susceptibility to other dengue-like symptoms from unknown causes.